Autoantibodies against Endophilin A2 as a novel biomarker are beneficial to early diagnosis of breast cancer.

Due to the lack of early symptoms, breast cancer is frequently overlooked, leading to distant metastases and multi-organ lesions that directly threaten patients' lives. We have identified a novel tumor marker, antibodies to endophilin A2 (EA2), to improve early diagnosis of breast cancer. Antibody levels of EA2 were analyzed in sera of patients with cancers of different origins and stages by indirect enzyme-linked immunosorbent assay (ELISA). Diagnostic accuracy and reference range were determined by the area under the receiver operating curve and distribution curve. The levels of EA2 antigen in sera were determined by sandwich ELISA. The levels of antibodies against EA2 were higher in sera of patients with breast cancer (P < 0.0001), liver cancer (P = 0.0005), gastric cancer (P = 0.0026), and colon cancer (P = 0.0349) than those in healthy controls, but not in patients with rectal cancer (P = 0.1151), leukemia (P = 0.7508), or lung cancer (P = 0.2247). The highest diagnostic value was for breast cancer, particularly in early cases (AUC = 0.8014) and those with distant metastases (AUC = 0.7885). The titers of EA2 antibodies in sera were correlated with levels of EA2 antigen in breast cancer patients. Antibodies to EA2 are novel blood biomarkers for early diagnosis of breast cancer that warrants further study in larger-scale cohort studies. Copyright © 2024 Elsevier B.V. All rights reserved.

Citation

Xiaomeng Li, Xiaowei Li, Kaige Zhang, Yanglong Guan, Meiyang Fan, Qian Wu, Yue Li, Rikard Holmdahl, Shemin Lu, Wenhua Zhu, Xiaoqin Wang, Liesu Meng. Autoantibodies against Endophilin A2 as a novel biomarker are beneficial to early diagnosis of breast cancer. Clinica chimica acta; international journal of clinical chemistry. 2024 Jun 15;560:119748

Mesh Tags

Substances

PMID: 38796051

search → result